Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Innovent Biologics Inc.

www.innoventbio.com/en/

Latest From Innovent Biologics Inc.

More Surufatinib Cheer For Chi-Med As Second NET Trial Stopped Early

Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.

Cancer Clinical Trials

Asia Deal Watch: BeiGene Gets Chinese Rights To Two EUSA Rare Disease Therapies

BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.

Deals Business Strategies

Coherus Acquires Bevacizumab Rights From Innovent

Coherus BioSciences has struck a deal with China’s Innovent Biologics that gives it US and Canadian rights to a bevacizumab biosimilar version of Avastin as well as an option to market Innovent’s rituximab rival to Rituxan in the US and Canada.

Deals Biosimilars

BeiGene's Brukinsa Fails In Head-To-Head But Hope Remains For Rare Indication

Days after bagging a US approval for its first global new drug, BeiGene was dealt a blow as its BTK inhibitor Brukinsa showed no significant superiority over class leader Imbruvica in Waldenström's macroglobulinemia, although the Chinese company remains hopeful for a possible approval.

Clinical Trials Blood & Coagulation Disorders
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Immune Disorders
  • Metabolic Disorders
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Innovent Biologics Inc.
  • Senior Management
  • Michael Yu, PhD, Pres. & CEO
    Ronald Ede, CFO
    Qinwei Zhou, PhD, COO
    Blake Salisbury, VP, Bus. Dev.
    Min Liu, Chief Commercial Officer
  • Contact Info
  • Innovent Biologics Inc.
    Phone: 512 69566088
    168 Dongping St., Suzhou Industrial Park
    Suzhou, 215123
    China
UsernamePublicRestriction

Register